1. MenB vaccines show lab cross-protection against MenX—but conjugates are still the gold standard In this laboratory study, investigators evaluated whether the protein-based meningococcal B vaccines 4CMenB (Bexsero)...
The story of early TBE research in the Soviet Union is more than a historical curiosity. It offers a vivid case study of how science, politics, and social conditions intertwine. It reminds us that medical breakthroughs...
Over roughly the past week, formal NITAG/agency outputs have largely reinforced and operationalized earlier 2026 policy decisions, while the most clearly “new” developments sit in World/Regional Immunization Week...
Global vaccine output remains highly concentrated among a few major producers. Here’s a snapshot of the latest estimates: (Note: Many companies do not publish per‑vaccine production figures; numbers marked with “~” are...
After years of disappointments, the C. difficile vaccine field is quietly repositioning itself. While GSK has officially dropped its own toxoid candidate from the pipeline, at least two other toxin‑based approaches—one...
Download Infographic Overview An adverse event (AE) is any medical event occurring after vaccination, regardless of whether it is causally related. A side effect is a medical event that is confirmed to be caused by a...
Introduction When it comes to vaccines and vaccination, nothing worries patients more than potential side effects. The fear that vaccination could lead to death or disability dates back to the time of Jenner and has...
The processes around vaccine licensure today are still built on a shared core: robust evidence for quality, safety, and efficacy, demonstrated through standardized preclinical testing, phased clinical trials, and...
Europe kicked off 2026 by adding more brains to the vaccine bureaucracy, designating a new WHO Collaborating Centre to help NITAGs turn messy evidence into cleaner policy decisions. In theory, this means fewer hand‑wavy...